1. Belgium Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Celyad Oncology SA

Celyad Oncology SA

0.28
USD
+0.08
(+40.00%)
6.70MMarket Cap
Mar 25Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.02
- -
1.07
0.37
0.28
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-3.53
-2.44
-3.43
-2.53
-5.86
-3.36
-2.29
-1.23
-1.7
-1.81
-0.33
-0.14
0.02
- -
Free Cash Flow per Basic Share
-2.72
-2.67
-3.32
-2.84
-4.71
-2.6
-2.3
-2.01
-1.73
-1.25
-0.63
-0.14
-0.16
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
2.67
3.79
11.97
9.76
4.82
4.65
3.27
2.22
1.93
0.19
0.15
0.01
0.05
0.05
Tangible Book Value per Share
1.18
2.33
6.73
4.44
1.12
1.63
0.68
-0.37
0.33
0.15
0.14
- -
0.05
0.05
Basic Weighted Avg Shares
4
7
8
9
10
11
13
14
16
23
26
41
43
41
Sales/Revenue/Turnover
- -
- -
- -
10
4
3
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
-13,621.23
-977,233.33
-260.98
-768.11
-1,007.61
-489,550
-522,020
- -
- -
-9,238.24
-3,154.3
-6,400
- -
Depreciation Expense
1
1
1
2
9
1
2
2
2
1
1
- -
- -
- -
Net Income, GAAP
-14
-16
-29
-24
-56
-37
-29
-17
-27
-41
-8
-6
1
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-11,269.18
-970,466.67
-235.78
-1,593.08
-1,201.51
-477,200
-344,080
- -
- -
-8,282.35
-3,131.18
3,952.38
- -
Working Capital
19
27
98
74
28
42
31
8
20
4
8
4
2
2
LT Debt
- -
- -
- -
1
1
1
3
3
2
- -
1
1
- -
- -
Total Equity
17
27
111
91
48
56
46
31
44
4
6
1
2
2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
45.74
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
46.42
- -
Return on Common Equity (%)
- -
-75.5
-42.15
-23.33
-81.48
-72.59
-56.58
-44.91
-71.05
-170.72
-159.08
-170.92
56.33
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
41
41
45
Market Capitalization
- -
18
6

Working Capital

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
7
2
3
Cash, Cash Equivalents & STI
4
1
2
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
4
2
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.23%
56.31%
376.71%
Free Cash Flow
-6.13%
-17.41%
19.01%
Net Income, GAAP
-9.32%
-23.23%
-114.25%
Sales/Revenue/Turnover
- -
- -
-88.71%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.33
2024
- -
- -
-0.14
2025
- -
- -
0.02

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Michel E. J. Lussier
Full Time Employees
3
Sector
Health technology
Industry
Biotechnology
Address
Axis Business Park Mont-Saint-Guibert WA Belgium 1435
IPO Date
Jul 5, 2013
Website
celyad.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Celyad Oncology S.A. (CYAD.BR) develops allogeneic CAR T-cell therapies targeting NKG2D ligands for the treatment of hematological and solid malignancies. The company offers proprietary platforms including off-the-shelf CAR T products such as CYAD-101 for acute myeloid leukemia and CYAD-02 for colorectal cancer; next-generation CAR T candidates like CYAD-200 series with enhanced persistence and reduced cytokine release syndrome; and supporting technologies for gene editing and manufacturing optimization. Headquartered in Mont-Saint-Guibert, Belgium, and founded in 2007 as a spin-off from the University of Louvain, Celyad Oncology operates primarily in Europe and the United States, focusing on oncology patients through clinical trials and partnerships with academic and biotech entities. In 2024, the company completed a strategic pivot by divesting its cardiovascular business to concentrate exclusively on oncology, rebranding from Celyad SA to Celyad Oncology S.A. to reflect this focus; it also secured €15 million in funding through a convertible bond issuance and announced a collaboration with PolyBioTech for manufacturing scale-up. Recent developments include the initiation of Phase 1 trials for CYAD-2004 in 2025 and expansion of its U.S. clinical footprint via IND filings with the FDA.